Literature DB >> 3855376

Chromosomal characteristics of chronic and blastic phases of Ph-positive chronic myeloid leukemia.

N Sadamori, M Matsunaga, E Yao, M Ichimaru, A A Sandberg.   

Abstract

To evaluate the appearance of chromosome changes, in addition to the Philadelphia (Ph) chromosome, as predictive and diagnostic parameters of transformation in chronic myeloid leukemia (CML), such changes were analyzed in the chronic phase (CP) and compared with those of the blastic phase (BP) of CML. The common chromosome changes observed in the CP were loss of a Y (-Y), trisomy 8 (+8), an isochromosome for the long arm of chromosome #17 [i(17q)], a double Ph (+Ph), reciprocal translocations, and partial deletions. In most patients with chromosome changes in addition to the Ph, the percentage of abnormal clones increased steadily during the CP and was accompanied by other chromosome changes shortly before or at the onset of the BP, except for cases with -Y or i(17q) clones. In general, most chromosome changes observed shortly before or at the BP were complex. These facts suggest that complex chromosome changes could be utilized as predictive and diagnostic parameters of blastic transformation in CML.

Entities:  

Mesh:

Year:  1985        PMID: 3855376     DOI: 10.1016/0165-4608(85)90127-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same.

Authors:  R P Gale; J F Apperley
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

3.  Prognostic significance of isochromosome 17q in hematologic malignancies.

Authors:  Dorota Koczkodaj; Justyna Muzyka-Kasietczuk; Sylwia Chocholska; Monika Podhorecka
Journal:  Oncotarget       Date:  2021-03-30

Review 4.  Guide to interpreting disease responses in chronic myeloid leukemia.

Authors:  Ilene Galinsky; Susan Buchanan
Journal:  J Adv Pract Oncol       Date:  2012-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.